Acute Myeloid Leukaemia (AML) is a blood cancer that develops rapidly with low survival rates and limited treatments. My research aims to identify leukaemia-specific weaknesses that can be therapeutically targetable, with the goal of improving survival rates for AML patients.

Learn more about my group's research

Dr Catherine Carmichael is Head of the Leukaemia Modelling and Therapeutic Discovery Research group within the Centre for Cancer Research at Hudson Institute.

Areas of interest

Blood cancer Childhood cancer

Research group

Leukaemia Modelling and Therapeutic Discovery


Dr Catherine Carmichael is a molecular cancer biologist whose research is focused on identifying the key mechanisms driving Acute Myeloid Leukaemia (AML) progression and developing novel therapeutic approaches to treat this devastating blood cancer.

Dr Carmichael’s specialist areas are the molecular and biological processes underpinning both normal and malignant blood cell development, and using sophisticated cellular and animal modelling approaches to identify therapeutically targetable molecular and biological dependencies of leukaemia cells.

She has made significant contributions to the understanding of the underlying molecular alterations that drive both inherited and acquired forms of myeloid and erythroid leukaemia.

Dr Carmichael has received more than $3 million in grant and fellowship funding from both National and State government agencies (NHMRC and Victorian Cancer Agency), as well as from philanthropic funding bodies such as the Leukaemia Foundation of Australia.


Awards and fellowships


Publication highlights